JP2012506429A - 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩 - Google Patents

真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩 Download PDF

Info

Publication number
JP2012506429A
JP2012506429A JP2011533151A JP2011533151A JP2012506429A JP 2012506429 A JP2012506429 A JP 2012506429A JP 2011533151 A JP2011533151 A JP 2011533151A JP 2011533151 A JP2011533151 A JP 2011533151A JP 2012506429 A JP2012506429 A JP 2012506429A
Authority
JP
Japan
Prior art keywords
magnesium
lipoate
lipoic acid
sequelae
diabetes mellitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011533151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012506429A5 (enExample
Inventor
ネルソン，ディアンナ，ジェー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioLink Life Sciences Inc
Original Assignee
BioLink Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioLink Life Sciences Inc filed Critical BioLink Life Sciences Inc
Publication of JP2012506429A publication Critical patent/JP2012506429A/ja
Publication of JP2012506429A5 publication Critical patent/JP2012506429A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2011533151A 2008-10-24 2008-10-24 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩 Pending JP2012506429A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/081128 WO2010047717A1 (en) 2008-10-24 2008-10-24 Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities

Publications (2)

Publication Number Publication Date
JP2012506429A true JP2012506429A (ja) 2012-03-15
JP2012506429A5 JP2012506429A5 (enExample) 2012-05-17

Family

ID=42119567

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533151A Pending JP2012506429A (ja) 2008-10-24 2008-10-24 真性糖尿病及びその共存症の処置に有用である、水に不溶な安定なＲ−（＋）−α−リポ酸塩

Country Status (5)

Country Link
US (2) US8222432B2 (enExample)
EP (1) EP2349322A4 (enExample)
JP (1) JP2012506429A (enExample)
CA (1) CA2741700A1 (enExample)
WO (1) WO2010047717A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US8597264B2 (en) * 2011-03-24 2013-12-03 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
EP3804742A1 (en) 2013-03-15 2021-04-14 3M Innovative Properties Company Wound healing compositions
US20200383946A1 (en) * 2019-05-07 2020-12-10 Aciont Inc. Lipoic acid formulations
CN115536631B (zh) * 2021-06-30 2024-01-30 江苏同禾药业有限公司 一种高纯度的右旋硫辛酸镁盐的制备方法
CN116041318B (zh) * 2022-12-29 2025-04-18 江苏恒沛药物科技有限公司 一种制备硫辛酸的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US20070015926A1 (en) * 2005-07-16 2007-01-18 Nanjing Rally Biochemical Inc. Method of preparing R-(+)-alpha-lipoic acid and its salt
WO2007149313A1 (en) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115589T3 (es) 1989-11-09 1998-07-01 Asta Medica Ag Medicamento que contiene acido r-alfa-liponico o acido s-alfa-liponico como sustancia activa.
US5349100A (en) * 1991-01-02 1994-09-20 Exxon Chemical Patents Inc. Chiral metallocene compounds and preparation thereof by creation of a chiral center by enantioselective hydride transfer
US5545745A (en) * 1994-05-23 1996-08-13 Sepracor, Inc. Enantioselective preparation of optically pure albuterol
US6524619B2 (en) * 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
IT1319195B1 (it) 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.
IT1319196B1 (it) 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US8324191B2 (en) * 2008-07-11 2012-12-04 Biolink Life Sciences, Inc Combined calcium, magnesium and vitamin D supplements
US8080674B2 (en) * 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
US20070015926A1 (en) * 2005-07-16 2007-01-18 Nanjing Rally Biochemical Inc. Method of preparing R-(+)-alpha-lipoic acid and its salt
WO2007149313A1 (en) * 2006-06-16 2007-12-27 Indigene Pharmaceuticals Inc. Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013019637; ＡＩＣｈＥ　Ｊｏｕｒｎａｌ Ｖｏｌ．４７，Ｎｏ．１, 2001, ｐ．２-５ *
JPN6013019638; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｒｏｍａｔｏｇｒａｐｈｙ Ｖｏｌ．５０３, 1990, ｐ．２５６-２５９ *

Also Published As

Publication number Publication date
WO2010047717A1 (en) 2010-04-29
CA2741700A1 (en) 2010-04-29
US8222432B2 (en) 2012-07-17
EP2349322A4 (en) 2011-11-23
US20110213022A1 (en) 2011-09-01
US20120283320A1 (en) 2012-11-08
EP2349322A1 (en) 2011-08-03

Similar Documents

Publication Publication Date Title
AU2016204931B2 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
US20080234380A1 (en) Compositions and method for treatment of chronic inflammatory diseases
US20120283320A1 (en) Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
US12257238B2 (en) Magnesium biotinate compositions and methods of use
EP2453743A1 (en) N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
US20180296594A1 (en) Solid oral dosage form for breast symptoms
US20240342147A1 (en) Magnesium picolinate compositions and methods of use
EP2065045A1 (en) Antioxidant for preventing and treating diseases caused by oxidative stress
EP2964207A1 (en) Composition for use in the treatment of polycystic ovary syndrome
KR101826994B1 (ko) 제어된 방출성의 아스코르빈산 함유 경구용 정제 조성물 및 그 분석방법
US20130296390A1 (en) Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate
US20070293572A1 (en) Anti-Fatigue Composition
US20170304359A1 (en) Oral iodine dosage form
CN117243957A (zh) 具有抗应激、抗焦虑和抗抑郁活性的药物及其基础上的组合物
WO2010115947A2 (en) Prolonged-release alfa-lipoic acid
WO2013018008A1 (en) Basic alpha lipoic acid solution and its uses
JP2013509443A (ja) 胃保持性の経口用高用量亜鉛調製物
US20090239914A1 (en) Phosphorus binder for treatment of renal disease
JP2862676B2 (ja) 亜鉛を補充された前立腺抽出物
JP2004203863A (ja) 抗糖尿病用組成物
JP2006089392A (ja) 生活習慣病改善食品および生活習慣病治療薬
WO2003055480A1 (en) Products for use in immunosuppressive therapy containing lipoic acid and a calcineurin inhibitor

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131001